Evaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 12, 2011, Pages 2643-2651

  Berger, Joachim ^a   Berger, Silke ^a   Jacoby, Arie S ^b   Wilton, Steve D ^c   Currie, Peter D ^a  

^a MONASH UNIVERSITY   (Australia)

^b VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

DMD; Duchenne muscular dystrophy; Dystrophin; Exon skipping; Muscle; Zebrafish

Indexed keywords

DYSTROPHIN; MESSENGER RNA;

ANIMAL; ARTICLE; DUCHENNE MUSCULAR DYSTROPHY; EVALUATION; EXON; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; PHENOTYPE; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC ANIMAL; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DYSTROPHIN; EXONS; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; ZEBRAFISH;

EID: 82455184945     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01260.x     Document Type: Article

References (24)

1. Klein CJ, Coovert DD, Bulman DE, et al. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet. 1992; 50: 950-9.
2. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002; 8: 253-61.
3. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357: 2677-86.
4. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009; 8: 918-28.
5. Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009; 30: 293-9.
6. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA. 2001; 98: 42-7.
7. McClorey G, Moulton HM, Iversen PL, et al. Antisense oligonucleotide-induced exon skipping restores dystrophin expressionin vitroin a canine model of DMD. Gene Ther. 2006; 13: 1373-81.
8. Zucconi E, Valadares MC, Vieira NM, et al. Ringo: discordance between the molecular and clinical manifestation in a golden retriever muscular dystrophy dog. Neuromuscul Disord. 2010; 20: 64-70.
9. Bulfield G, Siller WG, Wight PA, et al. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA. 1984; 81: 1189-92.
10. Bassett DI, Bryson-Richardson RJ, Daggett DF, et al. Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. Development. 2003; 130: 5851-60.
11. Berger J, Berger S, Hall TE, et al. Dystrophin-deficient zebrafish feature aspects of the Duchenne muscular dystrophy pathology. Neuromuscul Disord. 2010; 20: 826-32.
12. Granato M, van Eeden FJ, Schach U, et al. Genes controlling and mediating locomotion behavior of the zebrafish embryo and larva. Development. 1996; 123: 399-413.
13. Berger J, Currie P. The role of zebrafish in chemical genetics. Curr Med Chem. 2007; 14: 2413-20.
14. Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet. 2007; 8: 353-67.
15. Pelegri F. Mutagenesis. In: Nusslein-Volhard C, Dahm R, editors. Zebrafish: a practical approach. New York: Oxford University Press; 2002. p. 145-74.
16. Mitrpant C, Adams AM, Meloni PL, et al. Rational design of antisense oligomers to induce dystrophin exon skipping. Mol Ther. 2009; 17: 1418-26.
17. Corrado K, Mills PL, Chamberlain JS. Deletion analysis of the dystrophin-actin binding domain. FEBS Lett. 1994; 344: 255-60.
18. Guyon JR, Goswami J, Jun SJ, et al. Genetic isolation and characterization of a splicing mutant of zebrafish dystrophin. Hum Mol Genet. 2009; 18: 202-11.
19. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001; 10: 1547-54.
20. Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol. 2009; 65: 667-76.
21. Hoffman EP, Kunkel LM, Angelini C, et al. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology. 1989; 39: 1011-7.
22. Angelini C, Fanin M, Pegoraro E, et al. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. Neuromuscul Disord. 1994; 4: 349-58.
23. Nicholson LV, Johnson MA, Bushby KM, et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. J Med Genet. 1993; 30: 728-36.
24. Zhang MQ. Statistical features of human exons and their flanking regions. Hum Mol Genet. 1998; 7: 919-32.